Phase 4 N=132 RCT (Randomized Controlled Trial) of IV Acetaminophen for Post Cesarean Pain Relief
Cesarean Section · Pain, Postoperative
Primary: Total Oxycodone (mg) — 47.0; 65.0 mg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=20 Effect of Samples on Acne Treatment With Epiduo® Gel
Acne Vulgaris
Primary: Adherence to Study Medication — 86; 71 percentage of doses
Phase 4 N=1,366 VERtebral Fracture Treatment Comparisons in Osteoporotic Women
Postmenopausal Osteoporosis
Primary: Proportion of Participants With New Vertebral Fractures — 28; 64 Participants (with at least one event) — p=0.000094
Phase 4 N=35 COMFORT: A Multicenter, Open-label, Randomized, Crossover Study
Varicose Veins
Primary: Pain — 11.3; 9.5 units on a scale
Phase 4 N=36 Biomarker Study of Acamprosate in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Anterior Cingulate Cortex - Choline — 1.64; 1.54; 1.46; 1.58 mM
Phase 4 N=105 Sedation Methods During Cataract Surgery
Phacoemulsification · Cataract
Primary: Eye Mobility During Surgery (See Link to Study Protocol for Scale) — 1.39; 1.41; 1.31 units on a scale
Phase 4 N=570 Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment
Opioid Use Disorder
Primary: Time to Relapse (Intent to Treat Population) — 8.4; 14.4 weeks
Phase 4 N=2,092 Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing
Colon Cleansing
Primary: Distribution of the Overall Colon-cleansing Scale in Each Treatment Group. — 618; 243; 275; 423 Participants
Phase 4 N=165 Total Hip Arthroplasty (THA) Lumbar Plexus Verses Periarticular
Total Hip Arthroplasty
Primary: Maximum Postoperative Pain Score — 3.0; 4.0; 3.0 units on a scale — p=0.033
Phase 4 N=150 EVARREST™ Fibrin Sealant Patch Post-Market Study
Hemorrhage · Soft Tissue Bleeding
Primary: Safety Parameter - Incidence of Thromboembolic Events — 2; 7 Participants
Phase 4 N=115 Systemic Steroids for Peripheral Nerve Blocks
Osteoarthritis, Hip
Primary: Duration of Sensory Blockade — 18.5; 18.1; 19.6 hours
Phase 4 N=38 FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
HIV-1 Infection
Primary: Change in Levels of CD8+ T-cell Activation (Defined as the Percentage HLA-DR+/CD38+) From Baseline to Weeks 24 and 48 on ART — -4.01 % of CD8+ T-cells — p=0.001
Phase 4 N=32 Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients
Congenital Heart Diseases · Aortic Valve Disorder
Primary: Number of Patients Who Receive Preoperative Vancomycin and Cefazolin Who Develop a Surgical Site Infection Compared to Those Whose Received Only Cefazolin. — 0; 0…
Phase 4 N=875 Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
Relapsing Remitting Multiple Sclerosis
Primary: Participant Retention Rate Over 12 Months — 352; 125 participants
Phase 4 N=573 Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed
Infections, Bacterial
Primary: Ratio of Geometric Mean Concentrations (GMC) of Anti-protective Antigen (PA) Antibody (Ab) at 4 Weeks (Day 29) After the First AVA Dose (Prior to the Third AVA Dose)…